These results prompted the evaluation of recMAGE-A3+AS02 in a double-blind, randomized, placebo-controlled phase II study involving patients with completely resected MAGE-A3-expressing stage IB or II Non-Small Cell Lung Cancer (NSCLC) [10]. Here, MAGEA3 is linked to non-small cell lung carcinoma.